Peptris funding, investors and company details

Peptris is an emerging Pharmaceutical startup from Bengaluru, working in the space of Preclinical Drug Development, AI-powered Drug Discovery, Biotech. Founded by Amit Mahajan, Shridhar Narayanan, Narayanan Venkatasubramanian, Anand Budni.

Company: Peptris Technologies Private Limited
Sector: Pharmaceutical
Location: Bengaluru
Founders: Amit Mahajan, Shridhar Narayanan, Narayanan Venkatasubramanian, Anand Budni

Company overview

Peptris Technologies is an India-based AI-driven preclinical drug discovery company that focuses on rare diseases, cancer, and inflammatory conditions; by leveraging proprietary machine learning models, Peptris accelerates drug development through predictive analytics that assess potency, safety, and selectivity, reducing reliance on costly wet-lab trials, and has achieved a major milestone by licensing PEPR-124, India’s first AI-discovered drug candidate for Duchenne Muscular Dystrophy, to Revio Therapeutics, positioning itself as a pioneer in combining computational drug design with experimental validation to address unmet medical needs.

Funding rounds

Latest round (Series A): ₹70.00 Cr. ($ 7.71 Mn), 2026-02-18. Investors: Speciale Invest, Tenacity Ventures, BYT Ventures
Past round (Pre-Seed): $ 1.00 Mn (₹8.32 Cr.), 2023-12-19. Investors: Speciale Invest
Past round: ₹240.00 Cr. ($ 31.62 Mn), 2022-03-29. Investors: Amicus Capital Partners, Sharrp Ventures, Singularity Growth Opportunities Fund, RPSG Capital Ventures